相关实验视频
Updated: Jun 24, 2025

06:51
Mouse Model of Pressure Ulcers After Spinal Cord Injury
Published on: March 9, 2019
9.4K
在接受急性缺血性中风治疗的患者中,压力的发展
Esin Derin Cicek1, Ayper Önal Alkan2, Nihan Parasiz Yukselen3
1University of Health Sciences, Istanbul Fatih Sultan Mehmet Training and Research Hospital, Department of Radiology, Istanbul, Turkey.
Journal of wound care
|June 6, 2024
概括
接受急性缺血性中风 (AIS) 治疗的患者面临7.4%的发展压力的风险. 机械血栓切除术 (MT) 和较高的NIHSS分数增加了这种风险,需要针对风险人群制定有针对性的预防策略.
科学领域:
- 神经学 神经学
- 血管医学 血管医学
- 皮肤病学 皮肤病学
背景情况:
- 急性缺血性中风 (AIS) 是导致残疾的主要原因,患者通常需要密集的医疗干预.
- 压力 (PUs) 是住院患者的常见并发症,特别是那些行动能力有限和复杂的医疗条件.
- 了解AIS患者的PU发病率和风险因素对于改善患者的治疗结果和减少医疗负担至关重要.
研究的目的:
- 确定在接受急性缺血性中风 (AIS) 治疗的患者中压力 (PUs) 的发生率.
- 确定与该患者群体中PUs发展相关的并发症和混因素.
- 评估不同AIS治疗方式对PU发育的影响.
主要方法:
- 分析了242名因AIS治疗的患者队列,分为三个治疗组:单独使用静脉内组织等离子素激活剂 (tPA),单独使用机械血栓切除术 (MT),并结合tPA和MT.
- 使用国际分类系统对压力进行了分类.
- 进行了统计分析,以调查诸如年龄,治疗组,国家卫生研究院中风量表 (NIHSS) 评分,并发症和重症监护室 (ICU) 停留与PU发展相关的因素.
主要成果:
- 在AIS患者中,PU的总发病率为7.4%.
- 接受机械血栓切除 (MT) (12.1%) 或tPA和MT (15.7%) 患者的PU发病率明显高于仅接受tPA (2.3%) (p=0.001) 的患者.
- 入院时NIHSS得分较高 (p=0.010) 和住院时间较长 (p=0.000) 与PU发展有关,而年龄和并发症并不是显著因素.
结论:
- 接受AIS治疗,NIHSS得分高和/或接受机械血栓切除术的患者患压力的风险较高.
- 对于这些高风险的AIS患者,应实施积极和有针对性的预防措施,以减轻PU的发展.
- 进一步的研究可能会探索具体的干预措施,以减少在接受MT的AIS患者中PU发生率.
关键词:
国际压力分类系统 国际压力分类系统美国国立卫生研究院的中风量表.急性缺血性中风急性缺血性中风静脉静脉组织等离子素激活剂疗法机械血栓切除术是一种机械血栓切除术.压力的压力.一次性中风中风中风中风中风的发作 的发作 的发作伤口的伤口是伤口.伤口护理 伤口护理伤口上使用了伤口带.伤口愈合 伤口愈合更多相关视频
相关概念视频
Peptic Ulcer Disease IV: Management
87
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
87
Peptic Ulcer Disease V: Surgical Management and Nursing Care
288
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
288
Peptic Ulcer Disease I: Introduction
163
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
163
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
378
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
378
Peptic Ulcer Disease II: Pathophysiology
379
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
379

